Church & Dwight Co., Inc. Q1 2008 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 28, 2008. Church & Dwight Co., Inc. is a large accelerated filer incorporated in Delaware. The company operates three reportable segments: Consumer Domestic, Consumer International, and Specialty Products Division (SPD), alongside a Corporate segment. As of May 1, 2008, there were 66,478,398 shares of Common Stock outstanding.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $552.9 million | $514.3 million |
| Gross Profit | $224.1 million | $199.9 million |
| Gross Margin | 40.5% | 38.9% |
| Operating Income | $92.8 million | $82.1 million |
| Net Income | $56.2 million | $45.1 million |
| Diluted EPS | $0.81 | $0.66 |
| Operating Cash Flow | $62.7 million | $29.6 million |
| Total Debt | $747.9 million | $856.0 million (Dec 31, 2007) |
| Cash & Equivalents | $208.1 million | $249.8 million (Dec 31, 2007) |
| Net Debt | $539.8 million | $606.2 million (Dec 31, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7.5% year-over-year, driven by higher volume, price/mix, and a 1.5% favorable foreign exchange impact.
- Margin Expansion: Gross margin improved by 160 basis points to 40.5%, aided by the conversion to concentrated laundry detergent, manufacturing synergies, a diesel hedge contract, and lower slotting costs. These gains were partially offset by higher commodity and energy costs.
- Expense Increases: Marketing expenses rose $7.6 million due to increased advertising for acquired products (OGI), cat litter, and condoms. SG&A expenses increased $6.0 million, primarily due to a $5.6 million asset impairment charge at a foreign subsidiary and higher legal costs related to litigation with Abbott Laboratories.
- Debt Reduction: The company repaid $100.0 million of its accounts receivable securitization facility and $8.4 million of its Term Loan, reducing total debt significantly from the prior year-end.
- Asset Sale: The company sold its British subsidiary, Brotherton Specialty Products Ltd., for $11.2 million, recognizing a $3.0 million pre-tax gain.
Outlook, Risks, and Unusual Items
- Acquisition: On April 1, 2008, the company announced an agreement to acquire Del Pharmaceuticals, Inc. (Orajel brand) for $380.0 million, expected to close in July 2008. Funding will come from borrowings, increased securitization, and cash.
- Legal Proceedings: The company won a patent infringement lawsuit against Abbott Laboratories, with a jury awarding $14.6 million in damages. However, post-trial motions are pending. Conversely, Abbott has filed a counter-suit against the company.
- Regulatory Risks: The FDA has issued draft guidance regarding the spermicide nonoxynol-9 (N-9) in condoms. While the company believes its current labeling is compliant, future restrictions could impact sales and incur costs for obsolete inventory.
- Impairment Charges: The company recorded $3.4 million in tradename impairment charges and $1.5 million in property, plant, and equipment write-downs related to the Consumer International segment.
- Financial Covenants: Adjusted EBITDA for the quarter was $117.1 million. The leverage ratio (1.88) and interest coverage ratio (6.95) remain well within the limits of the company's credit facility.
Investor Verification Checklist
- Verify the status of post-trial motions in the Abbott Laboratories litigation and the potential impact of the counter-suit.
- Monitor the regulatory outcome of the FDA guidance on N-9 in condoms and its effect on the Trojan brand portfolio.
- Confirm the closing timeline and integration costs associated with the $380 million Orajel acquisition.
- Assess the sustainability of gross margin expansion given the expiration of the diesel hedge program and potential future commodity cost increases.
- Review the specific details of the $5.6 million asset impairment charge in the Consumer International segment to understand the long-term impact on that division.